“Know the Ropes - Balancing Costs and Quality in Health Care”.

13 to 16 July 2016

Universität Hamburg

Workshops

All Pre-conference workshops

13 July | 9 a.m. - 12 p.m.

ESA West 121

Dorte Gyrd-Hansen, COHERE, Department of Business and Economics & Department of Public Health, University of Southern Denmark

Using Stated Preference Methods to Guide Health Policy: Challen- ges, Pitfalls and Research Agendas

This workshop will present important issues relating to the elicitation of preferences using stated preference methods, and seek to present new research questions relating to current methods and interpretations. The validity of excluding so-called protest bidders, and the appropriateness of excluding preferences due to non-attendance will be discussed. Further topics will relate to how individual (consumer) and public (citizen) preferences may differ, and the underlying reasons for such discrepancies. Related to this is the issue of framing, preferences for public/private provision of health care services as well as altruism.

ESA West 122

Andrew Michael Jones, University of York

Data Visualisation and Health Econometrics

This pre-conference workshop will review econometric methods to model health care costs for prediction and forecasting, risk adjustment, resource allocation, technology assessment and policy evaluation. The workshop will focus on the principles and practice of data visualisation and statistical graphics and how these can enhance empirical analysis. Particular attention will be devoted to methods for skewed and fat-tailed distributions. Practical examples will show how these methods can be applied using Stata. Topics will include: an introduction to data visualisation; matching for preprocessing; data description and regression; generalised linear models; flexible parametric models; and semiparametric models.

ESA West 220

Frank Lichtenberg, Columbia University and National Bureau of Economic Research

Measuring the Impact of Biomedical Innovation on Longevity, Health, and Medical Expenditure

A substantial body of evidence indicates that biomedical innovation—the introduction and use of new drugs, devices, and procedures—is responsible for most of the recent gains in longevity and health. This workshop will survey econometric methods for analyzing the impact of biomedical innovation on longevity, health, and medical expenditure. We will consider several research designs (e.g. analysis of longitudinal disease-level data and of right-censored patient-level data), measures of innovation (e.g. the mean “vintage” of drugs and procedures), and review evidence from several countries (e.g. the USA, Portugal, Switzerland, Turkey, and Australia).

ESA West 222

Mathias Kifmann, Universität Hamburg

Paying Providers

This short course will give an overview of the theory on provider payment. The focus is on the implications of asymmetric information and incomplete contracts between payers and providers. We consider how payment systems can optimally balance the competing objectives of cost control, quality provision, rent extraction, and patient selection. The course provides a non-technical review of important contributions from the literature and gives a comprehensive overview of the main results. Pay-for-performance will be discussed in greater detail.

13 July | 1 p.m. - 4 p.m.

ESA West 221

Mark Britnell, Chairman & Partner of KPMG‘s Global Health Practice

KPMG Satellite Symposium: „How Can Different Stakeholders in the Health Sector be Better Aligned?“

KPMG Satellite Symposium: „How Can Different Stakeholders in the Health Sector be Better Aligned?“

ESA West 120

Beate Jahn, UMIT - Private Universität für Gesundheitswissenschaften, Medizinische Informatik und Technik GmbH

Introduction to Medical and Economic Decision Analysis (Decision-Analytic Modeling)

Course Level: Beginner

This course provides an introduction into decision-analytic modeling (DAM) a tool for costeffectiveness analysis, benefit-harm analysis and medical decision making. Participants will develop a basic understanding of:

  • Key concepts, definitions and goals of DAM
  • Creating the structure of a decision-analytic model
  • Measuring benefits, harms, patient preferences, costs and cost effectiveness
  • Application of modeling techniques (e.g., decision trees, state-transition models)
  • Uncertainty/sensitivity analyses

Practical examples will illustrate the main modeling steps. Modeling recommendations of the ISPORSMDM Joint Modeling Good Research Practices Task Force will be presented to allow participants assessing and judging the quality and validity of decision models. Strengths and limitations of DAM will be reviewed. This is a core short course of the Society for Medical Decision Making (SMDM). 

ESA West 121

Luigi Siciliani, University of York

Competition in Health Care Markets

This short 3-hour course will give an overview of theoretical and empirical methods which investigate the effect of hospital competition on quality of care. Empirical methods will cover cross-sectional and panel-data models, natural experiments, instrumental variables, and matching. The focus will be on illustrating the various methods used in the literature to identify the effect of competition (eg market structure) on quality of care and the key empirical findings, mainly from the UK and the US. Some alternative approaches to model competition (such as merger analysis, choice models and spatial econometrics) will also be selectively discussed.

ESA West 122

Thomas Siedler, Universität Hamburg

The Economics of Risky Health Behaviour

Risky health behaviours such as smoking, alcohol consumption, poor diets, no exercising, and illicit drug use are a leading source of preventable deaths. This course starts by reviewing theoretical models of risky health behaviour, encompassing (1) traditional approaches emphasizing utility maximization, and (2) more non-traditional models such as bounded rationality and hyperbolic time discounting. The main focus will be on the efficiency of policy strategies to influence smoking, exercise, alcohol consumption and illicit drug use, in particular subsidies and taxes, restrictions on purchase, cash incentives and information provision.